NDA 022106 · Shionogi
Doribax
Doripenem · Intravenous
NovelDiscontinuedLast checked: Nov 20, 2026Latest source record: Nov 13, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Oct 12, 2007
Approved uses
1
Original approval plus efficacy supplements
Registered trials
26
13 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- DORIBAX · DORIPENEM 500MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INTRAVENOUS · Discontinued
- DORIBAX · DORIPENEM 250MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INTRAVENOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Doripenem" as an intervention, any sponsor and status, largest first.
- Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or PyelonephritisPivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00229021 · 741 participants · Start Dec 2003
Drug: doripenum · For: Urinary Tract Infections; Pyelonephritis
- Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01599806 · 641 participants · Start Oct 2012 · Primary completion Aug 2014
Drug: Ceftazidime - Avibactam ( CAZ-AVI); Doripenem and 2 more · For: Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Sites: Detroit, Michigan; St Louis, Missouri; Indiana, Pennsylvania · 57 sites in all
- Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01595438 · 598 participants · Start Oct 2012 · Primary completion Aug 2014
Drug: Ceftazidime - Avibactam ( CAZ-AVI); Doripenem and 2 more · For: Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Sites: Sylmar, California; Royal Oak, Michigan; Lima, Ohio · 80 sites in all
- Doripenem in the Treatment of Complicated Intra-Abdominal InfectionsPivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00229060 · 483 participants · Start Mar 2004
Drug: doripenem · For: Bacterial Infections and Mycoses; Appendicitis; Cholecystitis and 2 more
- Doripenem in the Treatment of Complicated Intra-Abdominal InfectionsPivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00210938 · 478 participants · Start Mar 2004
Drug: Doripenem · For: Bacterial Infections and Mycoses; Appendicitis; Cholecystitis and 2 more
- Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or PyelonephritisPivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00210990 · 403 participants · Start Mar 2004
Drug: doripenem · For: Urinary Tract Infections; Pyelonephritis
- Doripenem in the Treatment of Ventilator-Associated PneumoniaPivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00211016 · 318 participants · Start Aug 2004
Drug: doripenem · For: Pneumonia; Ventilators, Mechanical
- To Compare Safety and Efficacy of Doripenem Versus Imipenem-Cilastatin in Patients With Ventilator-Associated PneumoniaPivotal-lookingTerminated
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00589693 · 274 participants · Start Apr 2008 · Primary completion Jun 2011
Drug: Doripenem; Imipenem-Cilastatin and 1 more · For: Ventilator-Associated Pneumonia
Sites: Jonesboro, Arkansas; Newark, Delaware; Washington D.C., District of Columbia · 100 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The risk of seizures among the carbapenems: a meta-analysis.
Cannon JP, Lee TA, Clark NM, et al. · J Antimicrob Chemother 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Doripenem Treatment during Continuous Renal Replacement Therapy.
Vossen MG, Wenisch JM, Maier-Salamon A, et al. · Antimicrob Agents Chemother 2015 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Worldwide threatening prevalence of carbapenem-resistant Pseudomonas aeruginosa.
Ahmadi MH, Fagheei Aghmiyuni Z, Bakhti S · Epidemiol Infect 2025 · Meta-Analysis
- Structural basis for carbapenem-hydrolyzing mechanisms of carbapenemases conferring antibiotic resistance.
Jeon JH, Lee JH, Lee JJ, et al. · Int J Mol Sci 2015 · Research Support, Non-U.S. Gov't, Systematic Review
- Pharmacokinetics of doripenem during high volume hemodiafiltration in patients with septic shock.
Tamme K, Oselin K, Kipper K, et al. · J Clin Pharmacol 2015 · Clinical Trial, Research Support, Non-U.S. Gov't
- Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems.
Zusman O, Avni T, Leibovici L, et al. · Antimicrob Agents Chemother 2013 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Shionogi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.